A Phase II trial of Elacestrant (RAD1901) in patient with advanced breast cancer

Trial Profile

A Phase II trial of Elacestrant (RAD1901) in patient with advanced breast cancer

Planning
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Elacestrant (Primary)
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Radius Health Inc.
  • Most Recent Events

    • 03 Aug 2017 According to a Radius Health media release,the US FDA agreed that a single-arm monotherapy Phase 2 study of under 200 patients is appropriate and provided additional feedback on the proposed clinical protocol, including confirmation that the primary endpoint will be objective response rate ("ORR"), coupled with durability of response ("DOR").
    • 03 Aug 2017 According to a Radius Health media release, the US FDA has indicated that, depending on the study results, which must demonstrate superiority to then available therapies, this Phase 2 trial could be considered a pivotal study for accelerated approval as long as the company has commenced a confirmatory study by the time of NDA submission.
    • 04 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top